For example, high levels of EGFR were associated with resistance to lenvatinib in HCC patients because the inhibition of FGFR by lenvatinib led to aberrant activation of the EGFR/PAK2/ERK5 signaling axis.[14] Further studies are needed to illustrate the mechanisms of drug resistance and overcome it. This evidence concerns the gene PAK2 and hepatocellular carcinoma.